Company Announcements

Faron Pharmaceuticals Ltd.

("Faron" or "the Company")

Faron announces Capital Markets Day to be held on 22 October 2024

Press release, 7 October 2024

TURKU, FINLAND - Faron Pharmaceuticals Ltd. (AIM: FARN, First North: FARON), a clinical-stage biopharmaceutical company focused on tackling cancers via novel immunotherapies, today announces that it will host a Capital Markets Day for investors, analysts and media on Tuesday, 22 October 2024 at 08:00 am (EDT) / 13:00 pm (BST) / 15:00 pm (EEST). Speakers include Dr. Mika Kontro, MD, PhD, Associate Professor at the University of Helsinki, Mr. Ralph Hughes, MSc, BSc, Senior Vice President at PharmaVentures and members of Faron's senior management team.

The agenda is as follows:

·    Opening remarks

·    Faron's strategy and key focus areas - Dr. Juho Jalkanen, MD, PhD, CEO

·    BEXMAB clinical data - Dr. Mika Kontro, MD, PhD, principal investigator of the BEXMAB trial

·    BEXMAB MDS market assessment - Mr. Ralph Hughes, MSc, BSc

·    Faron's development plan for solid tumors - Dr. Petri Bono, MD, PhD, CMO

·    Who benefits from bexmarilimab and why - Future Addressable Markets - Dr. Maija Hollmén, PhD, CSO

·    Q&A session

·    Closing remarks

As part of the event, Juho Jalkanen, CEO of Faron, will discuss Faron's strategy and key focus areas for the coming years. Dr. Kontro will share updated survival data from the ongoing BEXMAB Phase I/II trial. Mr. Hughes will present the results of recently conducted market research in MDS. Dr. Bono will provide Faron's development plan for solid tumours, discuss bexmarilimab's further potential as first-in-class immune-oncological treatment and introduce the Company's new Scientific Advisory Board (SAB).

"I am delighted to be hosting this Capital Markets Day with our invited speakers and members of Faron's senior management team who will provide important insights into the recent developments and further plan to bring the promise of immunotherapy to a broader patient group," said Dr. Juho Jalkanen, Chief Executive Officer of Faron. "In addition to providing the latest BEXMAB survival update, we will present the clinical development plan for bexmarilimab in solid tumors. The event will also feature an introduction to our new Scientific Advisory Board with world-leading clinical investigators," said Dr. Petri Bono, Chief Medical Officer at Faron.

The event will be held as a live hybrid event. It will begin at 08:00 am (EDT) / 13:00 pm (BST) / 15:00 pm (EEST) on Tuesday, October 22, 2024. The duration of the event will be some 2.5 hours.

Webcast registration link: https://faron.videosync.fi/cmd-2024

Live participation

In addition to the webcast, there are a limited number of seats available to attend the Capital Markets Day at Eliel in Sanomatalo at Töölönlahdenkatu 2, Helsinki. To register, please contact

investor.relations@faron.com no later than 2:00 pm (EEST) on Friday, 18 October 2024. Please note that places are limited, and you will receive a separate email if you get a seat confirmed.

A link to a recording of this Capital Markets Day will be made available on the "Investors" section on Faron's website at:  https://www.faron.com/investors.

For more information please contact:

ICR Consilium
Mary-Jane Elliott, David Daley, Lindsey Neville
Phone: +44 (0)20 3709 5700
E-mail: faron@consilium-comms.com

Cairn Financial Advisers LLP, Nomad

Sandy Jamieson, Jo Turner

Phone: +44 (0) 207 213 0880

Peel Hunt LLP, Broker

Christopher Golden, James Steel

Phone: +44 (0) 20 7418 8900

Sisu Partners Oy, Certified Adviser on Nasdaq First North

Juha Karttunen

Phone: +358 (0)40 555 4727

Jukka Järvelä

Phone: +358 (0)50 553 8990

About BEXMAB

The BEXMAB study is an open-label Phase I/II clinical trial investigating bexmarilimab in combination with standard of care (SoC) in the aggressive hematological malignancies of acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS). The primary objective is to determine the safety and tolerability of bexmarilimab in combination with SoC (azacitidine) treatment. Directly targeting Clever-1 could limit the replication capacity of cancer cells, increase antigen presentation, ignite an immune response, and allow current treatments to be more effective. Clever-1 is highly expressed in both AML and MDS and associated with therapy resistance, limited T cell activation and poor outcomes.

About bexmarilimab

Bexmarilimab is Faron's wholly owned, investigational immunotherapy designed to overcome resistance to existing treatments and optimize clinical outcomes, by targeting myeloid cell function and igniting the immune system. Bexmarilimab binds to Clever-1, an immunosuppressive receptor found on macrophages leading to tumor growth and metastases (i.e. helps cancer evade the immune system). By targeting the Clever-1 receptor on macrophages, bexmarilimab alters the tumor microenvironment, reprogramming macrophages from an immunosuppressive (M2) state to an immunostimulatory (M1) one, upregulating interferon production and priming the immune system to attack tumors and sensitizing cancer cells to standard of care.

About Faron Pharmaceuticals Ltd

Faron (AIM: FARN, First North: FARON) is a global, clinical-stage biopharmaceutical company, focused on tackling cancers via novel immunotherapies. Its mission is to bring the promise of immunotherapy to a broader population by uncovering novel ways to control and harness the power of the immune system. The Company's lead asset is bexmarilimab, a novel anti-Clever-1 humanized antibody, with the potential to remove immunosuppression of cancers through reprogramming myeloid cell function. Bexmarilimab is being investigated in Phase I/II clinical trials as a potential therapy for patients with hematological cancers in combination with other standard treatments. Further information is available at www.faron.com.